Illumina forecasts 2025 revenue largely below estimates
(Reuters) – Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling subdued demand for its genetic tests and diagnostic tools, sending shares down nearly 4% in extended trading. Diagnostic tool makers such as Illumina have witnessed reduced spending from biotech clients in the past two years, but recent …
Illumina forecasts 2025 revenue largely below estimates Read More »









